Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-14 4:45 pm Sale | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -2,850,000 (Position Closed) | View |
| 2023-02-14 3:01 pm Sale | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Rock Springs Capital Management LP | 0 0.000% | -2,581,299 (Position Closed) | View |
| 2023-02-14 2:26 pm Sale | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Avidity Partners Management LP | 2,040,000 4.100% | -2,365,000 (-53.69%) | View |
| 2023-02-06 3:02 pm Sale | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | WELLINGTON MANAGEMENT GROUP LLP | 0 0.000% | -2,869,650 (Position Closed) | View |
| 2022-11-04 4:42 pm Sale | 13D | PHASEBIO PHARMACEUTICALS INC C PHASQ | NEW ENTERPRISE ASSOCIATES 13 LP | 0 0.000% | -6,641,634 (Position Closed) | View |
| 2022-07-19 11:30 am Purchase | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | MAI Capital Management | 2,675,376 5.800% | 2,675,376 (New Position) | View |
| 2022-02-14 6:24 pm Purchase | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Rock Springs Capital Management LP | 2,581,299 5.370% | 1,266,925 (+96.39%) | View |
| 2022-02-14 4:12 pm Sale | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Rosalind Advisors Inc. | 707,467 1.500% | -1,900,390 (-72.87%) | View |
| 2022-02-14 4:11 pm Unchanged | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | RA CAPITAL MANAGEMENT L.P. | 2,850,000 5.900% | 0 (Unchanged) | View |
| 2022-02-11 7:52 pm Purchase | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Avidity Partners Management LP | 4,405,000 9.200% | 120,000 (+2.80%) | View |
| 2022-02-04 09:29 am Purchase | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | WELLINGTON MANAGEMENT GROUP LLP | 2,869,650 5.970% | 944,570 (+49.07%) | View |
| 2022-02-01 2:42 pm Unchanged | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | JOHNSON & JOHNSON JNJ | 1,607,044 3.300% | 0 (Unchanged) | View |
| 2021-11-10 08:51 am Sale | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | WELLINGTON MANAGEMENT GROUP LLP | 1,925,080 4.010% | -4,089,809 (-67.99%) | View |
| 2021-08-10 07:57 am Purchase | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | WELLINGTON MANAGEMENT GROUP LLP | 6,014,889 12.540% | 4,447,233 (+283.69%) | View |
| 2021-05-19 2:25 pm Purchase | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Rosalind Advisors Inc. | 2,607,857 5.400% | 2,607,857 (New Position) | View |
| 2021-03-24 4:30 pm Purchase | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | RA CAPITAL MANAGEMENT L.P. | 2,850,000 6.000% | 2,850,000 (New Position) | View |
| 2021-03-22 4:05 pm Purchase | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Avidity Partners Management LP | 4,285,000 9.400% | 4,285,000 (New Position) | View |
| 2021-02-16 4:32 pm Sale | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Rock Springs Capital Management LP | 1,314,374 4.480% | -337,500 (-20.43%) | View |
| 2021-01-11 09:10 am Sale | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | WELLINGTON MANAGEMENT GROUP LLP | 1,567,656 5.340% | -2,324,600 (-59.72%) | View |
| 2020-11-16 4:59 pm Purchase | 13G | PHASEBIO PHARMACEUTICALS INC C PHASQ | Rock Springs Capital Management LP | 1,651,874 5.630% | 526,874 (+46.83%) | View |